New research has been published in the journal Allergy that looks at how the body undergoes immunological changes that may support remission of peanut allergies in children. Previously there was little known how the body successfully acquires remission of the peanut allergy, and this article uses probiotic peanut oral immunotherapy to analyze this more in depth.
 
The study included 62 children from Australia aged between 1 and 10 years who were peanut allergic. The children were split into two groups, one that received a combination treatment of probiotic and oral immunotherapy, and another which acted as a placebo. The trial lasted 18 months, and at the end of the treatment, it was found that 74% of those in the treatment group achieved remission, while only 4% in the placebo group. The key finding from this study was that the researchers gained insights into how remission was acquired; specific gene networks and their rewiring were identified as drivers of peanut allergy remission.
 
As a result of this research, there is a better understanding of how probiotic oral immunotherapy can lead to peanut allergy remission in children. This will help in identifying targeted practices to induce remission in those patients who have a peanut allergy.

Ashley, S.E., et al. (2022) Remission of peanut allergy is associated with rewiring of allergen-driven T helper 2-related gene networks. Allergy.

Join us

Sign up to become a member of the INC and discover the benefits of INC membership. Or subscribe and have access to our magazine, industry newsletters and industry directory.

Privacy Preference Center